Cohort of STEMI Patients

Completed

• Conditions: Myocardial Infarction
• Interventions: Other: STEMI PATIENT Cohort

• Registration Number: NCT02822638
• Lead Sponsor: Hospices Civils de Lyon

Brief Summary

Ischemic heart disease is the leading cause of mortality in industrialized countries. ST elevated acute myocardial infarction is one of its most frequent and deadly manifestation. In the last 20 years, STEMI mortality has been reduced by 50% with the advent of timely reperfusion (primary percutaneous intervention) and significant progression in pharmacologic intervention.

However, death and heart failure incidence after STEMI remain elevated: up to 20% at one year.

Also, therapeutic management following international guidelines is standardized toward a "one-size fits all" therapeutic management.

In order to continue improving myocardial infarction outcomes, there is a need to better understand and individualize therapeutic targets such myocardial reperfusion injury, post reperfusion inflammation, adverse left ventricular (LV) remodeling ....

This knowledge will allow us to propose new therapeutic strategies and in the long run strive towards personalized medicine.

The aim objective of this cohort of STEMI patients is to identify new biological markers of injury and prognosis.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2009-08
• Primary Completion: 2016-05
• Study Completion: 2016-05
• Status Verified: 2016-06
• Study First Submitted: 2016-06-30
• Study First Submitted QC: 2016-06-30
• Last Update Submitted: 2016-06-30
• Study First Posted: 2016-07-04
• Last Update Posted: 2016-07-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1204

Inclusion Criteria

• Age> 18 years
• Diagnosis of STEMI defined by ST segment elevation ≥ 0.2 mV in 2 contiguous leads on a 12-lead ECG.
• Primary PCI within 12 hours of symptoms onset.

Read More

Exclusion Criteria

• Diagnosis of STEMI not confirmed by angiography
• Refusal to participate in the study or to sign the consent
• Inability to give information to the subject about the study
• Lack of medical social coverage
• Deprivation of civil rights

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
STEMI PATIENT Cohort	STEMI PATIENT Cohort	STEMI PATIENT Cohort

Primary Outcome Measures

Name	Time	Method
Change in Creatine Kinase	Day 0	Dosage of Creatine Kinase at hospital admission and 4 hours after PCI
Change in Troponin	Day 0	Dosage of Troponin at hospital admission and 4 hours after Percutaneous coronary intervention (PCI)

Secondary Outcome Measures

Name	Time	Method
Left ventricular ejection fraction (LVEF)	24 hours after PCI (Day 1)	LVEF measured by echocardiography
New York Heart Association (NYHA) Class	at admission (Day 0)

Trial Locations

Locations (1)

Hôpital Cardiovasculaire Louis Pradel 28, Avenue du Doyen Lépine; 🇫🇷 Bron, France